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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYPluripotent stem cells are a promising tool for mechanistic studies of tissue development, drug screening, and cell-based therapies. Here,
we report an effective and mass-producing strategy for the stepwise differentiation of mouse embryonic stem cells (mESCs) and mouse
and human induced pluripotent stem cells (miPSCs and hiPSCs, respectively) into osteoblasts using four small molecules (CHIR99021
[CHIR], cyclopamine [Cyc], smoothened agonist [SAG], and a helioxanthin-derivative 4-(4-methoxyphenyl)pyrido[40,30:4,5]thieno
[2,3-b]pyridine-2-carboxamide [TH]) under serum-free and feeder-free conditions. The strategy, which consists of mesoderm induction,
osteoblast induction, and osteoblast maturation phases, significantly induced expressions of osteoblast-related genes and proteins in
mESCs,miPSCs, andhiPSCs. In addition,whenmESCs defective in runt-related transcription factor 2 (Runx2), amaster regulator of osteo-
genesis, were cultured by the strategy, theymolecularly recapitulated osteoblast phenotypes of Runx2 null mice. The present strategy will
be a platform for biological and pathological studies of osteoblast development, screening of bone-augmentation drugs, and skeletal
regeneration.INTRODUCTION
The limited number of osteoblasts that can be obtained
from animals hinders the performance of extensive studies
on protein interactions, transcriptional networks, and epi-
genetics in osteoblast development. Therefore, pluripotent
stem cell-based osteogenic differentiationmay be an attrac-
tive model for such studies, given the pluripotency and
capacity for self-renewal of stemcells. Although several stra-
tegies havebeenused todifferentiate pluripotent stemcells,
including embryonic stem cells (ESCs) and induced plurip-
otent stem cells (iPSCs) into osteoblasts (Bilousova et al.,
2011; Buttery et al., 2001; Li et al., 2010; Kao et al., 2010;
Kawaguchi et al., 2005; Phillips et al., 2001; Tai et al.,
2004; Ye et al., 2011; zur Nieden et al., 2003), none of these
is a stepwise differentiation strategy that uses small mole-
cule inducers and serum-free monolayer cultures without
the formation of embryoid bodies (EBs).
Using the combination of a mitogen-activated protein
kinase kinase (MEK) inhibitor, PD0325901 (PD03), and a
glycogen synthase kinase 3 (GSK3) inhibitor, CHIR99021
(CHIR), which will hereafter be referred to as 2i, mouse
ESCs (mESCs) are maintained in a ground state (Ying
et al., 2008). CHIR activates canonical Wnt signaling byStesuppressing the degradation of b-catenin (Bain et al.,
2007). Canonical Wnt signaling cues also specify the dif-
ferentiation of germ layers and multipotent stem cells
into mesodermal cells (Davis and Zur Nieden, 2008). We
recently described the gene regulatory networks underly-
ing canonical Wnt signaling-mediated control of meso-
derm differentiation and pluripotency in mESCs (Zhang
et al., 2013).
The formation of osteoblasts is a sequential process.
In mesoderm-derived skeletons, cells in the lateral plate
mesoderm or the paraxial mesoderm give rise to skeletal
progenitors, which then differentiate into bone-forming
osteoblasts and cartilage-forming chondrocytes (Akiyama
et al., 2005). We and others have shown that hedgehog
(Hh) signaling is essential for normal osteoblast develop-
ment, particularly for the specification of osteo-chondro-
progenitors into osteoblast precursors, which express
runt-related transcription factor 2 (Runx2), a transcription
factor essential for bone formation (Hojo et al., 2012;
Long et al., 2004; St-Jacques et al., 1999); the smoothened
(SMO) agonist (SAG), a Hh signaling activator, promoted
early osteoblast differentiation in perichondrial cells,
which consist of osteo-chondroprogenitors (Hojo et al.,
2012). This finding suggested that SAG could efficientlym Cell Reports j Vol. 2 j 751–760 j June 3, 2014 j ª2014 The Authors 751
Figure 1. Optimization of Mesoderm
Induction and Osteoblast Induction in
mESCs
(A) The effect of the 5-day treatment with
CHIR on mesoderm differentiation and the
suppression of the pluripotent state in
mESCs. 2i-cultured mESCs were treated for
5 days with CHIR at different concentra-
tions. The mRNA expression levels were
determined using RT-quantitative PCR (RT-
qPCR). The data are expressed as the mean ±
SEM from three independent experiments.
See also Figure S1.
(B) The effect of the 14-day treatment with
SAG plus TH on osteoblast differentiation of
mESC-derived mesodermal cells. The mESCs
were cultured with 30 mM CHIR for 5 days,
then with (gray bars) or without (white
bars) 1 mM SAG and 1 mM TH for an addi-
tional 14 days. The mRNA expression was
determined using RT-qPCR. The data are
expressed as the mean ± SEM from four in-
dependent experiments.
(C) The effect of Cyc on mesoderm induction
and subsequent osteoblast induction in
mESCs. mESCs were cultured with 30 mM
CHIR for 5 days in the presence or absence
of 5 mM Cyc and treated for 14 days with SAG
plus TH. The mRNA expression was deter-
mined using RT-qPCR on days 5 and 19,
respectively. The data are expressed as
the mean ± SEM from four independent
experiments.
(D) A schematic showing the three-phase
strategy for osteoblast differentiation from
mESCs using the four small molecules under
chemically defined conditions.
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Moreover, it also indicated that SAG alone might not be
sufficient to direct the differentiation of these precursors
into mature osteoblasts. In terms of molecules inducing
osteoblast maturation, we identified the helioxanthin-de-
rivative 4-(4-methoxyphenyl)pyrido[40,30:4,5]thieno[2,3-
b]pyridine-2-carboxamide (TH) as an osteogenic small
molecule that acts on preosteoblasts in a bone morphoge-
netic protein (BMP)-dependent manner (Ohba et al.,
2007b). Furthermore, we recently reported the combinato-
rial effect of SAG and TH on the differentiation of mesen-
chymal cells into osteoblasts (Maeda et al., 2013).
Based on these findings, we hypothesized that pluripo-
tent stem cells could be efficiently differentiated into oste-
oblasts under defined conditions by sequentially treating
the cells with the above-mentioned small molecules in an
appropriate manner. The present study was designed to752 Stem Cell Reports j Vol. 2 j 751–760 j June 3, 2014 j ª2014 The Authorestablish a stepwise differentiation protocol for osteoblast
differentiation from pluripotent stem cells by utilizing
the small molecule inducers under serum-free and feeder-
free conditions.RESULTS AND DISCUSSION
We initially attempted to differentiate 2i-cultured mESCs
into mesodermal cells by activating canonical Wnt
signaling with CHIR in 2i culture media. CHIR upregulated
the mesoderm-related genes T and Mixl1 in a dose-depen-
dent manner relative to day 0 (Figure 1A; Figure S1A avail-
able online). The expression of the pluripotency-related
genes Nanog, Pou5f1, and Sox2 was suppressed in cells
treated with high concentrations of CHIR relative to
day 0 (Figures 1A and S1A). In addition, the expression ofs
(legend on next page)
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of the mesoderm-related genes was associated with higher
expression of osteoblast-related genes in subsequent osteo-
blast induction (Figure S1B). Therefore, we selected the
5-day treatment protocol using 30 mM CHIR for the meso-
derm induction of mESCs. To induce osteoblast differen-
tiation of the mESC-derived mesoderm cells, we then
cultured them in 2i culture media containing 1 mM SAG,
1 mM TH, and other osteogenic supplements (Jaiswal
et al., 1997). Runx2, Sp7, and Ibsp were upregulated
following treatment for 2 weeks with SAG plus TH relative
to the control group (Figure 1B). Thus, the stepwise differ-
entiation from mESCs into osteoblasts via mesoderm for-
mation was achieved using the three small molecules
CHIR, SAG, and TH.
Given the roles of Hh signaling during the development
of the CNS (Martı´ and Bovolenta, 2002), recombinant Hh
proteins or SAGs have been used to differentiate pluripo-
tent stem cells into motor neurons (Nizzardo et al., 2010).
Moreover, 2i-cultured ESCs preferentially differentiate
into ectoderm lineages rather than mesoderm lineages
(Marks et al., 2012). These findings led us to examine
whether the suppression of Hh signaling during the meso-
derm induction would block neuro-ectoderm specifica-
tion, resulting in enhanced osteoblast differentiation. The
combinatorial use of the Hh signaling inhibitor cyclop-
amine (Cyc) and CHIR during the 5-day mesoderm induc-
tion induced the downregulation of Sox1 on day 5 and led
to increased osteoblast differentiation (Figure 1C).
As shown in Figure 1D, we propose an optimized strategy
for promoting osteoblast differentiation from mESCs un-
der chemically defined conditions. This strategy consists
of three phases: the maintenance of mESCs using 2i plus
leukemia inhibitory factor (LIF) culture, mesoderm induc-
tion by CHIR in combination with Cyc-mediated sup-
pression of neuro-ectoderm differentiation, and osteoblast
induction by SAG and TH. Given that Cyc induces SMO
translocation to the primary cilium despite its inhibitoryFigure 2. Characterization of mESC-Derived Cells Generated Using
(A) Expressions of pluripotency-related (Pou5f1, Nanog, and Sox2), m
related (Sox17 and Gata4), and osteoblast-related genes (Runx2, Sp7,
and 23 (black bars) and cultured calvarial osteoblasts isolated from
expression data are shown in the dotted rectangular box with the small
eight independent experiments. *p < 0.05 versus day 0; **p < 0.01 v
day 0. See also Figures S2A–S2C.
(B) A schematic showing the four-phase strategy for directing mESCs
and expression of GFP in 2.3 kb Col1a1-GFP mESCs cultured according
(C) Protein expressions of the osteoblast-related markers in 2.3 kb Col1
The arrow shows the surface of the cell cluster. Scale bars, 100 mm. N
(D) Quantification of cells expressing osteoblast-related marker prot
positive for both DAPI and markers in total of DAPI-positive cells an
(E and F) von Kossa staining (E) and alizarin red staining (F) on days
754 Stem Cell Reports j Vol. 2 j 751–760 j June 3, 2014 j ª2014 The Authoreffect onHh signaling (Wang et al., 2009), the accumulated
SMO in the cilium may result in increased sensitivity to
subsequent SAG treatment, which may also contribute to
the osteoblast differentiation by SAG and TH during the
osteoblast induction phase. SAG and TH cooperatively
induce osteoblast differentiation, possibly through SAG-
mediated specification into an osteoblast lineage and TH-
mediated promotion of late osteoblast differentiation
(Hojo et al., 2013; Maeda et al., 2013; Ohba et al., 2007b).
Gene expression patterns inmESCs cultured according to
this strategy are shown in Figure 2A. Pou5f1, Nanog, and
Sox2 were significantly downregulated on day 19, indi-
cating that the mESCs gradually exited from the pluripo-
tent state as differentiation progressed. T and Mixl1 were
upregulated by mesoderm induction (day 5) and in turn
were downregulated by osteoblast induction (day 19).
Sox1, Sox17, andGata4, which are ectoderm and endoderm
marker genes, were not altered throughout the culture.
These data suggested that the present strategy specifically
directs pluripotent cells toward a mesodermal cell fate.
The osteoblast-related genes, Runx2, Sp7, Col1a1, and
Ibsp, were upregulated during the osteoblast induction
phase (day 19) relative to day 0; Runx2, Sp7, Col1a1, and
Ibsp were upregulated approximately 128-, 91-, 7,680-,
and 147,300-fold, respectively. However, the 19-day cul-
ture was not long enough for the cells to express Bglap, a
bona fide marker of mature osteoblasts; culturing the cells
for an additional 4 days in the absence of SAG or TH
induced a 145-fold upregulation of Bglap.
Expressions of the osteoblast-related genes in the
induced cells were higher than or comparable to those in
cultured mouse primary osteoblasts (Figure 2A). Expres-
sions of osteoblast-related transcription factors in the
induced cells were comparable to those in freshly isolated
mouse osteoblasts (fresh mObs), although the expressions
of matrix genes in the induced cells were not as high as
those in the fresh mObs (Figure S2A). When gene expres-
sions were compared between the present strategy and anthe Present Strategy for Osteoblast Differentiation
esoderm-related (T and Mixl1), ectoderm-related (Sox1), endoderm-
Col1a1, Ibsp, and Bglap) on days 0 (white bars), 5 (gray bars), 19,
mouse neonates (Ob; hatched bars). The Sox1, Sox17, and Gata4
er scale of the y axis. The data are expressed as the mean ± SEM from
ersus day 0; ***p < 0.001 versus day 0; N.S., nonsignificant versus
into mature osteoblasts. The lower panels indicate the morphology
to the present strategy. Scale bars, 100 mm.
a1-GFP mESCs cultured according to the present strategy on day 19.
uclei and SP7 are shown in pseudocolor. See also Figure S2D.
eins. The data are expressed as the mean of percentages of cells
alyzed ± SEM from three independent experiments.
5, 19, and 23 in mESCs cultured according to the present strategy.
s
Figure 3. Differentiation of miPSCs into Osteoblasts
(A) A schematic showing the strategy for inducing osteoblast differentiation of miPSCs. The lower panels show the morphology of colonies
of miPSCs and induced cells on days 0, 5, 19, and 23. Scale bars, 100 mm.
(B) Expressions of pluripotency-related (Nanog), mesoderm-related (T and Mixl1), and osteoblast-related genes (Runx2, Sp7, Col1a1, Ibsp,
and Bglap) on days 0 (white bars), 5 (gray bars), 19, and 23 (black bars) in miPSCs. The data are expressed as the mean ± SEM from six
independent experiments. *p < 0.05 versus day 0; **p < 0.01 versus day 0; ***p < 0.001 versus day 0.
(C) Protein expressions of the osteoblast-related markers in CAG-GFP miPSCs cultured according to the present strategy on day 23. RUNX2,
SP7, and GFP are shown in pseudocolor. The arrow shows the surface of the cell cluster. Scale bars, 100 mm.
(legend continued on next page)
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present strategy induced significantly lower expressions
of Sox17 and Gata4 on day 19 and higher expressions of
Runx2, Sp7, Col1a1, Ibsp, and Bglap on day 19 or 23 than
the conventional method (Figure S2B). The present strat-
egy is likely to differentiate mESCs into an osteoblast line-
age more specifically than the conventional method, at
least partly by avoiding their differentiation into unfavor-
able lineages. When we examined gene expressions at
several time points during the culture (Figure S2C), the
expression profile resembled a proposed model for the Hh
signaling-mediated specification of skeletal progenitors
into Runx2-positive osteoblast precursors and their subse-
quent differentiation into osteoblasts in skeletal develop-
ment (Rodda and McMahon, 2006).
Thus, we established a strategy to direct mESCs toward a
mature osteoblast cell fate by sequentially using four small
molecules, CHIR, Cyc, SAG, and TH, under chemically
defined conditions. This protocol involves the addition of
a fourth osteoblast maturation phase to the three-phase
strategy described earlier (Figure 2B). The effectiveness of
the strategy was further confirmed by the expression of
GFP on days 19 and 23 in mESCs engineered to express
GFP under the control of an osteoblast-specific rat 2.3 kb
Col1a1 promoter (2.3 kb Col1a1-GFP mESCs) (Figure 2B)
(Ohba et al., 2007a).
We used immunohistochemistry to measure the expres-
sion of RUNX2, SP7, and GFP in the induced 2.3 kb
Col1a1-GFP mESCs. RUNX2, SP7, and the 2.3 kb Col1a1-
GFP were highly expressed in the induced cells on day
19. RUNX2 and SP7 were colocalized in nuclei, and 2.3
kb Col1a1-GFP was largely observed in the cytoplasm and
nuclei (Figure 2C). The average percentages of RUNX2-,
SP7-, and GFP-positive cells were 78% ± 3%, 66% ± 5%,
and 45% ± 1%, respectively (Figure 2D). The different per-
centages of thosemarkers in our culture are consistent with
the physiological process of osteoblast development. The
percentages enable us to estimate the final yields of each
osteoblastic population, given that 900,000 ± 150,000
cells/cm2 were obtained on day 19 of the culture from
100,000 cells/cm2 of input. Pluripotency markers were
hardly expressed in the induced cells on day 19 (Fig-
ure S2D). The average percentages of OCT4-, NANOG-,
and SOX2-positive cells were 2.3% ± 0.6%, 1.5% ± 0.7%,
and 9.0% ± 3.1%, respectively (Figure S2D). In addition,
BRACHYURY (T), a mesodermmaker, was ubiquitously ex-
pressed in the induced cells on day 5 (Figure S1C). von(D) Alizarin red staining on days 5, 19, and 23 in miPSCs cultured ac
(E) Alizarin red staining-based quantification of calcification levels
relative to day 5 in each cell type. ***p < 0.001 versus day 5 in each ce
mean ± SEM from six independent experiments.
756 Stem Cell Reports j Vol. 2 j 751–760 j June 3, 2014 j ª2014 The AuthorKossa staining and alizarin red staining revealed the uni-
form formation of calcified cell clusters by days 19 and 23
(Figures 2E and 2F). These results indicate that the present
strategy induced both the expression of osteoblast-related
genes and the calcification of matrix, two key features of
osteoblasts.
To confirm that the present strategy could be useful for
investigating osteoblast development using gene-manipu-
lated mESCs in vitro, we examined whether Runx2/
mESCs cultured using the present strategy could molecu-
larly recapitulate osteoblast phenotypes in Runx2/ mice
(Figure S3A). Runx2/ mESCs showed similar transient
upregulation of T to Runx2+/+ mESCs, but Sp7 and Bglap
were hardly upregulated in Runx2/ mESCs on day 19
compared to day 0 and day 5. Importantly, the expression
of the early osteoblast marker gene Ibsp showed a 212-fold
upregulation in Runx2/ mESCs on day 19, although the
level was lower than that observed in Runx2+/+ mESCs. In
alizarin red staining, the calcification level of Runx2/
mESCs was lower than that of Runx2+/+ ones on both
days 19 and 23 (Figures 2F, S3B, and S3C). These obser-
vations were consistent with the bone phenotypes of
Runx2/ mice (Komori et al., 1997; Tu et al., 2012).
Thus, the present strategy can at least partially recapitulate
physiological osteoblast development andwill be useful for
analyzing osteoblast development using gene-manipu-
lated ESCs in vitro.
Because the direct differentiation of mouse iPSCs
(miPSCs) and human iPSCs (hiPSCs) into osteogenic cells
has been previously reported by Bilousova et al. (2011),
Kao et al. (2010), and Levi et al. (2012), we applied the
present strategy to 2i-adapted miPSCs established from
fibroblasts of mice expressing GFP (CAG-GFP miPSCs)
(Okabe et al., 1997) (Figure 3A). Nanog was downregulated
throughout the culture compared to day 0. T and Mixl1
were transiently upregulated by mesoderm induction on
day 5. The osteoblast-related genes Runx2, Sp7, Col1a1,
Ibsp, and Bglap were upregulated by the osteoblast induc-
tion (Figure 3B). RUNX2 and SP7 proteins were highly
expressed in the induced cells on day 23, and their signals
were merged with that of GFP (Figure 3C), suggesting that
CAG-GFP miPSCs were differentiated into cells expressing
osteoblast-related proteins. Calcified cell clusters were
formed on days 19 and 23 (Figure 3D). In the comparison
of calcification levels between mESCs and miPSCs, both
cell types were calcified at a similar level on day 19; mESCs
then showed more calcification on day 23 (Figure 3E).cording to the present strategy.
in mESCs and miPSCs cultured according to the present strategy,
ll type; N.S., nonsignificant; yp < 0.05. The data are expressed as the
s
(legend on next page)
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mESCs and miPSCs into osteoblasts by sequentially treat-
ing the cells with four small molecules, CHIR, Cyc, SAG,
and TH, under chemically defined conditions.
Finally, we cultured hiPSCs according to the present
strategy with somemodifications (Figure 4A; Supplemental
Experimental Procedures). hiPSCs formed colonies on day
0. In the mesoderm induction phase, these colonies were
disrupted, but the cells generated some clusters upon
CHIR and Cyc treatment. The remaining cells proliferated
and formed colonies by days 19 and 23 of the osteoblast
induction andmaturation phases (Figure 4A). Gene expres-
sion patterns in the cultured hiPSCs are shown in Figure 4B.
NANOG was downregulated during induction. T and
MIXL1 were transiently upregulated on day 5. RUNX2
and SP7 were also upregulated on day 5; their expression
levels were maintained and statistically significant on day
23 compared with day 0. IBSP and COL1A1 were signifi-
cantly upregulated on days 19 and 23, respectively. The
contribution of Hh signaling to osteoblast-related gene
expression might cause differences in the gene expression
pattern between human and mouse cells, as previously re-
ported by Plaisant et al. (2009). On day 23, RUNX2 protein
was evenly expressed in cell clusters, and SP7was expressed
in the periphery, where RUNX2 and SP7 were colocalized
(Figure 4C). Calcification on days 19 and 23 was signifi-
cantly higher than that on day 5 (Figures 4D and 4E). These
results suggest that the present strategy is capable of differ-
entiating hiPSCs into osteoblasts.
This study demonstrates the robust generation of osteo-
blasts from pluripotent stem cells using four small mole-
cules under serum-free and feeder-free conditions. This
strategy requires no or very little use of confounding fac-
tors derived from serum and feeder cells. Such a simple,
small molecule-based system offers significant benefits
for skeletal research and regenerative medicine by mini-
mizing costs and maintaining the stability of the inducers.
However, this study has two major limitations. First,
the target molecules of TH are unclear; we are currently
screening for these targets using a proteomic approachFigure 4. Differentiation of hiPSCs into Osteoblasts
(A) A schematic showing the strategy for inducing osteoblast different
of hiPSCs and induced cells on days 0, 5, 19, and 23. Scale bars, 100
(B) Expressions of pluripotency-related (NANOG), mesoderm-related (
and IBSP) on days 0 (white bars), 5 (gray bars), 19, and 23 (black b
independent experiments. *p < 0.05 versus day 0; **p < 0.01 versus
(C) Protein expressions of RUNX2 and SP7 in hiPSCs on day 23. Low
rectangular box in the left-upper panel. Nuclei are shown in pseudo
100 mm.
(D) Alizarin red staining on days 5, 19, and 23 in hiPSCs cultured acc
(E) Alizarin red staining-based quantification of calcification in hiPSCs
**p < 0.01 versus day 5. The data are expressed as the mean ± SEM f
758 Stem Cell Reports j Vol. 2 j 751–760 j June 3, 2014 j ª2014 The Authorwith a modified TH carrying a moiety that binds to mag-
netic beads via an amide bond. Second, we used Matrigel,
which was not a fully defined reagent (Hughes et al.,
2010), for hiPSCs to maintain cell viability. Because we
observed a substantial level of hiPSC death on the Matri-
gel-coated plates during the initial 5-day induction, this
strategy might be deleterious for the survival and differen-
tiation of hiPSCs. In future studies, there will be a need for
defined reagents suppressing the cell death of hiPSCs as
well as reagents that will eliminate residual pluripotent
cells (Ben-David and Benvenisty, 2011; Tang et al., 2011);
the 2.3 kb Col1a1-GFP may be used to sort out osteoblasts.
In conclusion, the present stepwise differentiation strategy
offers a tool for in vitro mechanistic studies of osteoblast
development and stem cell-based therapies for massive
bone defects, although the strategy will need to be further
optimized to enable broader application.EXPERIMENTAL PROCEDURES
Differentiation of mESCs into Osteoblasts
mESCs were seeded at 100,000 cells/cm2 in gelatin-coated 6-well
plates and cultured for 24 hr in 2i culture media (see Supple-
mental Experimental Procedures) supplemented with CHIR
(Wako Pure Chemical Industries, 039-20831; Axon Medchem,
1386), PD0325901 (Wako; 163-24001), and LIF (Millipore;
ESG1107). After briefly washing the cells with PBS, the 5-day in-
duction protocol was initiated to differentiate the cells toward a
mesoderm lineage. 2i culture media without CHIR, PD0325901,
or LIF were used as basal media during the differentiation culture
and supplemented with small molecules for each differentiation
step as shown below. The mesoderm induction was achieved by
culturing the cells with 30 mM CHIR and 5 mM Cyc (Enzo Life Sci-
ences; BML-GR334) in 2i culture media. To induce osteoblast dif-
ferentiation, we then cultured the cells for 14 days in 2i culture
media supplemented with 50 mg/ml ascorbic acid phosphate
(AsAP) (Sigma-Aldrich; A4034), 10 mM b-glycerophosphate
(b-GP) (Sigma-Aldrich; G9422), 0.1 mM dexamethasone (Dex)
(Wako; 041-18861), 1 mM SAG (Calbiochem; 566660), and 1 mM
TH (synthesized by Takeda Chemical Industries). For osteoblast
maturation, the cells were cultured for an additional 4 days in 2iiation of hiPSCs. The lower panels show the morphology of colonies
mm.
T and MIXL1), and osteoblast-related genes (RUNX2, SP7, COL1A1,
ars) in hiPSCs. The data are expressed as the mean ± SEM from six
day 0.
er panels show magnified views of the region marked by a dotted
color. The arrow shows the surface of the cell cluster. Scale bars,
ording to the present strategy.
cultured according to the present strategy, relative to that of day 5.
rom six independent experiments.
s
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Generating Osteoblasts from Pluripotent Stem Cellsculturemedia supplementedwithAsAP, b-GP, andDex. The culture
media were replaced daily. TH can be distributed upon request.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2014.04.016.
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